Head and neck squamous cell carcinoma (HNSCC) tumours are associated with high mortality despite advances in therapy. The monoclonal antibody cetuximab (Erbitux®) has been approved for the treatment of advanced HNSCC. However, only a subset of HNSC patients receiving cetuximab actually responds to treatment, underlining the need for a means to tailor treatments of individual patients. The aim of the present study was to investigate the effect of cetuximab treatment on tumour growth, on tumour partial oxygen pressure as measured by LiPc electron paramagnetic resonance oximetry and on the expression of proteins involved in tumour growth, metabolism and hypoxia. Two HNSCC cell lines, UT-SCC-2 and UT-SCC-14, were used to generate xenografts on ...
EPR oximetry using an implantable paramagnetic probe was used to quantify the partial pressure of ox...
Angiogenesis, a marker of cancer development, affects response to radiotherapy sensibility. This pre...
PURPOSE: Optimal Head and Neck Squamous Cell Carcinoma (HNSCC) patient selection for anti-EGFR-based...
Head and neck squamous cell carcinoma (HNSCC) tumours are associated with high mortality despite adv...
Head and neck squamous cell carcinoma (HNSCC) tumours are associated with high mortality despite adv...
BACKGROUND AND PURPOSE: Previous experiments have shown that application of the anti-EGFR monoclonal...
Despite advances in the head and neck squamous cell carcinoma (HNSCC) treatment modalities, drug res...
Contains fulltext : 171117.pdf (publisher's version ) (Open Access)Overexpression ...
PURPOSE: Optimal Head and Neck Squamous Cell Carcinoma (HNSCC) patient selection for anti-EGFR-based...
It is well recognized that tumor hypoxia is a critical determinant for response to therapy. The effe...
Despite advances in the head and neck squamous cell carcinoma (HNSCC) treatment modalities, drug res...
Epidermal growth factor receptor (EGFR) is overexpressed in the majority of head and neck cancers. T...
PURPOSE: Radiation therapy cures malignant tumors of the head and neck region more effectively when ...
BACKGROUND AND PURPOSE: EGFR-inhibitor Cetuximab (C225) improves the efficacy of radiotherapy in onl...
PURPOSE: Optimal head and neck squamous cell carcinoma (HNSCC) patient selection for Anti-EGFR-based...
EPR oximetry using an implantable paramagnetic probe was used to quantify the partial pressure of ox...
Angiogenesis, a marker of cancer development, affects response to radiotherapy sensibility. This pre...
PURPOSE: Optimal Head and Neck Squamous Cell Carcinoma (HNSCC) patient selection for anti-EGFR-based...
Head and neck squamous cell carcinoma (HNSCC) tumours are associated with high mortality despite adv...
Head and neck squamous cell carcinoma (HNSCC) tumours are associated with high mortality despite adv...
BACKGROUND AND PURPOSE: Previous experiments have shown that application of the anti-EGFR monoclonal...
Despite advances in the head and neck squamous cell carcinoma (HNSCC) treatment modalities, drug res...
Contains fulltext : 171117.pdf (publisher's version ) (Open Access)Overexpression ...
PURPOSE: Optimal Head and Neck Squamous Cell Carcinoma (HNSCC) patient selection for anti-EGFR-based...
It is well recognized that tumor hypoxia is a critical determinant for response to therapy. The effe...
Despite advances in the head and neck squamous cell carcinoma (HNSCC) treatment modalities, drug res...
Epidermal growth factor receptor (EGFR) is overexpressed in the majority of head and neck cancers. T...
PURPOSE: Radiation therapy cures malignant tumors of the head and neck region more effectively when ...
BACKGROUND AND PURPOSE: EGFR-inhibitor Cetuximab (C225) improves the efficacy of radiotherapy in onl...
PURPOSE: Optimal head and neck squamous cell carcinoma (HNSCC) patient selection for Anti-EGFR-based...
EPR oximetry using an implantable paramagnetic probe was used to quantify the partial pressure of ox...
Angiogenesis, a marker of cancer development, affects response to radiotherapy sensibility. This pre...
PURPOSE: Optimal Head and Neck Squamous Cell Carcinoma (HNSCC) patient selection for anti-EGFR-based...